13 hrs ago
Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort ...
Galectin Therapeutics , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the Company will hold a webcast on Tuesday, July 29, 2014 at 8:30 a.m. Eastern Daylight Time to discuss the findings from cohort 2 of a Phase 1 clinical trial evaluating its galectin inhibitor GR-MD-02 in fatty liver ... (more)
Thu Jul 24, 2014
Pulmonary Fibrosis Foundation Launches National PFF Ambassador Program
While launching today, PFF Ambassadors have already begun making an impact during speaking engagements, including last month during a Team PFF event in "The purpose of the PFF Ambassador program is to engage with the larger community and cover all aspects of disease education.
Wed Jul 23, 2014
Tests suggest limitations to Vertex's cystic fibrosis treatment
Investors and patients were exuberant last month when Vertex Pharmaceuticals released results from clinical trials showing that cystic fibrosis patients' lung function improved on an experimental two-drug regimen.
Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped
A powerful drug combo may not be as effective against cystic fibrosis as previously thought.
Tue Jul 22, 2014
Guardian Storage Marketing Director Raises Funds for Cystic Fibrosis Foundation
Christina Alvino, marketing manager for Guardian Storage, a self-storage operator with properties in Colorado and Pennsylvania, has been named as one of Pittsburgh's 50 Finest for 2014, a group that will raise money to benefit the Cystic Fibrosis Foundation .
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of...
Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the first patient has been dosed in cohort 1 of the Company's Phase 1B clinical trial evaluating GR-MD-02 in combination with ipilimumab in patients with metastatic melanoma.
Mon Jul 21, 2014
iBio, Inc. Appoints To Clinical Advisory Board
Dr. Silver is one of the world's leaders in clinical care and investigation of systemic sclerosis and scleroderma-like conditions.
Grapes & Grain event offers fine wine and beer to benefit Cystic Fibrosis Foundation
With red or white, blush, bubbly, or brew, guests will make a toast to health August 1 at the Grapes & Grain Fine Wine and Craft Beer Tasting.
New cystic fibrosis drug shows great promise
CLOSEUP of new miracle CF drug that costs $300,000 a year in front of all the other drugs and inhalers etc.
Cystic Fibrosis Might Be Two Diseases
The CFTR protein forms a tunnel that crosses a cell's membrane , allowing chloride or bicarbonate ions to pass through.
Sat Jul 19, 2014
Tulalip Great Strides raises $44K for cystic fibrosis
More than 300 walkers turned out to help raise $44,000 and counting for the Cystic Fibrosis Foundation during the Tulalip Great Strides Walk July 12. Anna Lester, development manager for the Washington and Alaska chapter of CFF, explained that the top three teams in the Tulalip walk's sixth year generated nearly $20,000.
The Chronicle Herald
More energy, clearer airways: Cystic fibrosis drug working for Greenwood man
Tim Vallillee, who lives with a rare form of cystic fibrosis, says he has experienced new-found endurance and other huge health benefits since he started taking the drug Kalydeco in May. While that may not sound like a huge feat for many 46-year-old men, it is for Vallillee, who suffers from a rare form of cystic fibrosis.
Fri Jul 18, 2014
NC Senate plan to overhaul state Medicaid program draws fire from doctors and hospitals
The North Carolina plan was presented by state senators during a Wednesday meeting of the Senate Rules and Operations Committee.
Wed Jul 16, 2014
Wall Street Journal
A Costly Drug Is Denied, And Medicaid Takes Heat
LITTLE ROCK, Ark.-Vertex Pharmaceuticals Inc.'s $300,000-a-year cystic-fibrosis drug has sparked a legal battle here, where the state's Medicaid program is restricting access to the expensive therapy.
FDA to Host Meeting on Patient Focused Drug Development for IPF
The FDA registered notice in the July 8, 2014 edition of the Federal Register that on September 26, 2014, the FDA is conducting a public meeting on Patient-Focused Drug Development for idiopathic pulmonary fibrosis .
Agile Nabs $1.5M NIH Grant for CF Therapy
The company's technology platform capitalizes on a chemical produced by the sea sponge to break up bacterial clumps called biofilms.
Mon Jul 14, 2014
Anthera Pharmaceuticals Announces Acquisition of Sollpura For...
Anthera Pharmaceuticals, Inc. today announced that it has acquired Sollpura , a novel investigational Pancreatic Enzyme Replacement Therapy from Eli Lilly and Company.
Tyler Morning Telegraph
Teen fights for cystic fibrosis care, research
A Tyler teenager traveled to Washington, D.C., recently to advocate for drug research and health care for people with cystic fibrosis.
Boehringer awaits FDA approval of lung fibrosis drug
Two months after Boehringer Ingelheim Pharmaceuticals said Phase III trials on a new drug called nintedanib reduced the rate of lost lung function, the U.S. Food and Drug Administration has accepted the company's new drug application and given it a priority review designation.
A room of her own
Greendale's Hailee Hedstrom, 11, was asked that question by Make-A-Wish Wisconsin, and without hesitation, she chose a backyard clubhouse.